Business
Grant of awards under Long Term Incentive Plan
AOTI, Inc. announced that on April 22, 2026, performance share awards were granted under its Long Term Incentive Plan to its CEO, CFO, and COO. The CEO received 678,471 awards, the CFO received 377,099 awards, and the COO received 270,672 awards, all with an exercise price of £0.37. These awards will vest in three years, contingent upon achieving specific Adjusted EBITDA and Adjusted EBITDA margin performance conditions measured over a three-year period ending December 31, 2028. Disclaimer*
About this update from Aoti, Inc.
23 April 2026 AOTI, INC. (the "Company" or "Group" or "AOTI") Grant of performance share awards to CEO, CFO and COO under Long Term Incentive Plan AOTI, INC. (AIM: AOTI), a medical technology group focused on delivering outcomes-based care at home, by more durable healing of wounds and the prevention of amputations, announces that on 22 April 2026, the Company granted awards over ordinary shares in the form of options (Performance Awards) under the AOTI Long Term Incentive Plan (LTIP) to Mike Griffiths, CEO, Jayesh Pankhania, CFO, and Anthony Moffatt, COO, who are Persons Discharging Managerial Responsibilities (PDMR), as detailed below: PDMR Role Number of Performance Awards Exercise Price (GBP) Mike Griffiths CEO 678,471 0.37 Jayesh Pankhania CFO 377,099 0.37 Anthony Moffatt COO 270,672 0.37 The Performance Awards will vest three years from the grant date conditional on meeting three-year performance conditions as described below. 50% of an award is subject to an Adjusted EBITDA 1 performance condition measured over a three-year period ending 31 December 2028. 50% of an award is subject to an Adjusted EBITDA margin 2 performance condition measured over a three-year period ending 31 December 2028. 1 Adjusted EBITDA is an unaudited non-GAAP measure: Earnings before interest, taxation, depreciation, amortisation and non-underlying items. 2 Adjusted EBITDA margin is Adjusted EBITDA divided by Revenue END AOTI, INC. Dr. Mike Griffiths, Chief Executive Officer Jayesh Pankhania, Chief Financial Officer +44 (0)20 3727 1000 [email protected] Peel Hunt LLP (Nominated Adviser and Joint Broker) Dr. Christopher Golden, James Steel +44 (0)20 7418 8900 Panmure Liberum Limited (Joint Broker) Emma Earl, Will Goode, Mark Rogers Rupert Dearden +44 (0)20 3100 2000 FTI Consulting (Financial PR & IR) Ben Atwell, Simon Conway, Natalie Garland-Collins +44 (0)20 3727 1000 [email protected] ABOUT AOTI, INC. AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO 2 ® ) therapy has demonstrated in differentiating, robust, double-blinded randomised controlled trials (RCT) and real-world evidence (RWE) studies to more durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalisations and 71 per cent reduction in amputations over 12 months. TWO 2 ® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO 2 ® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. TWO 2 ® therapy has also recently received positive coverage recommendations from the Federal Joint Committee (G-BA) in Germany and National Institute for Health and Care Excellence (NICE) in the United Kingdom. Also see www.aotinc.net 1. Details of the person discharging managerial responsibilities/person closely associated a) Name 1. Mike Griffiths 2. Jayesh Pankhania 3. Anthony Moffatt 2. Reason for notification a) Position / status 1. CEO 2. CFO 3. COO b) Initial notification / amendment Initial Notification 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name AOTI, INC. b) LEI 213800ZGCNDSTWIRK687 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument Ordinary Shares b) Identification code US03690C1027 c) Nature of transactions Award under the AOTI LTIP d) Price(s) and volume(s) Exercise Price: 1. GBP0.37 2. GBP0.37 3. GBP0.37 Volume: 1. 678,471 2. 377,099 3. 270,672 e) Aggregated Information - Aggregated volume - Price As for d) above f) Date of the transactions 22 April 2026 g) Place of the transactions Outside a trading venue